A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells

Biomaterials

Volumn 30, Issue 4, 2009, Pages 649-657

  Veiseh, Omid ^a   Kievit, Forrest M ^a   Gunn, Jonathan W ^a   Ratner, Buddy D ^b   Zhang, Miqin ^a  

^a University of Washington   (United States)

^b University of Washington   (United States)

Author keywords

Cancer targeting; Chlorotoxin; Gene therapy; Nanoparticle; Nanotechnology

Indexed keywords

ABS RESINS; AMINES; CYTOLOGY; GENE TRANSFER; GENETIC ENGINEERING; LIGANDS; NANOPARTICLES; NANOSTRUCTURED MATERIALS; NANOSTRUCTURES; NUCLEIC ACIDS; ORGANIC ACIDS; POLYMERS; TOXICITY;

ALEXA FLUORS; CANCER CELLS; CANCER TARGETING; CANCER THERAPIES; CANCER.; CHLOROTOXIN; COMPLEXING; DISEASED TISSUES; FUNCTIONALIZED; GENE CARRIERS; GENE DELIVERIES; GENE THERAPIES; GENE THERAPY; GENE TRANSFECTIONS; HIGH EFFICIENCIES; MEDULLOBLASTOMA; NEAR INFRARED; PEGYLATION; POLYETHYLENIMINE; TARGETED DELIVERIES; TARGETED GENE DELIVERIES; TO MANY; TRANSFECTION EFFICIENCIES; TUMOR CELLS;

CELLS;

CHLOROTOXIN; COPOLYMER; LIGAND; NANOPARTICLE; POLYETHYLENEIMINE; TOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOCOMPATIBILITY; CANCER CELL; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC TRANSFECTION; GLIOMA CELL; MOUSE; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN BINDING; RAT;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIC AMP; ELECTROPHORESIS, AGAR GEL; ENDOCYTOSIS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; NANOSTRUCTURES; NEOPLASMS; POLYETHYLENE GLYCOLS; RATS; RECEPTORS, CELL SURFACE; SCORPION VENOMS; TRANSFECTION; TRANSGENES;

ALEXA;

EID: 56449088717     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.10.003     Document Type: Article

References (36)

1. Stewart B.W., and Kleihues P. World cancer report (2003), World Health Organization Press, Geneva
2. Ries L., Melbert D., Krapcho M., Stinchcomb D.G., Howlader N., Horner M.J., et al. SEER cancer statistics review, 1975-2005. In: NCI (Ed) (2007), SEER, Bethesda, MD. Available from:
3. Alton E., Ferrari S., and Griesenbach U. Progress and prospects: gene therapy clinical trials (part 2). Gene Ther 14 22 (2007) 1555-1563
4. Li S.D., and Huang L. Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther 13 18 (2006) 1313-1319
5. McNeish I.A., Bell S.J., and Lemoine N.R. Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. Gene Ther 11 6 (2004) 497-503
6. Palmer D.H., Young L.S., and Mautner V. Cancer gene-therapy: clinical trials. Trends Biotechnol 24 2 (2006) 76-82
7. Verma I.M., and Somia N. Gene therapy - promises, problems and prospects. Nature 389 6648 (1997) 239-242
8. Pack D.W., Hoffman A.S., Pun S., and Stayton P.S. Design and development of polymers for gene delivery. Nat Rev Drug Discov 4 7 (2005) 581-593
9. Edelstein M.L., Abedi M.R., and Wixon J. Gene therapy clinical trials worldwide to 2007-an update. J Gene Med 9 10 (2007) 833-842
10. Jang J.H., Lim K.I., and Schaffer D.V. Library selection and directed evolution approaches to engineering targeted viral vectors. Biotechnol Bioeng 98 3 (2007) 515-524
11. Kodama K., Katayama Y., Shoji Y., and Nakashima H. The features and shortcomings for gene delivery of current non-viral carriers. Curr Med Chem 13 18 (2006) 2155-2161
12. Putnam D. Polymers for gene delivery across length scales. Nat Mater 5 6 (2006) 439-451
13. Ohlfest J.R., Freese A.B., and Largaespada D.A. Nonviral vectors for cancer gene therapy: prospects for integrating vectors and combination therapies. Curr Gene Ther 5 6 (2005) 629-641
14. Glover D.J., Lipps H.J., and Jans D.A. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 6 4 (2005) 299-310
15. Ogris M., and Wagner E. Targeting tumors with non-viral gene delivery systems. Drug Discov Today 7 8 (2002) 479-485
16. Wagner E. Targeting tumors with non-viral gene delivery systems. J Gene Med 5 3 (2003) S7-S8
17. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6 9 (2006) 688-701
18. Boussif O., Lezoualch F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in-vivo - polyethylenimine. Proc Natl Acad Sci U S A 92 16 (1995) 7297-7301
19. Godbey W.T., Wu K.K., and Mikos A.G. Poly(ethylenimine) and its role in gene delivery. J Controlled Release 60 2-3 (1999) 149-160
20. Benns J.M., Mahato R.I., and Kim S.W. Optimization of factors influencing the transfection efficiency of folate-PEG-folate-graft-polyethylenimine. J Controlled Release 79 1-3 (2002) 255-269
21. Kunath K., Merdan T., Hegener O., Haberlein H., and Kissel T. Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. J Gene Med 5 7 (2003) 588-599
22. Zanta M.A., Boussif O., Adib A., and Behr J.P. In vitro gene delivery to hepatocytes with galactosylated polyethylenimine. Bioconjug Chem 8 6 (1997) 839-844
23. Zeng J.M., Wang X., and Wang S. Self-assembled ternary complexes of plasmid DNA, low molecular weight polyethylenimine and targeting peptide for nonviral gene delivery into neurons. Biomaterials 28 7 (2007) 1443-1451
24. Germershaus O., Merdan T., Bakowsky U., Behe M., and Kissel T. Trastuzumab-polyethylenimine-polyethylene glycol conjugates for targeting Her2-expressing tumors. Bioconjug Chem 17 5 (2006) 1190-1199
25. Chiu S.H., Ueno N.T., and Lee R.J. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin (R)) conjugated polyethylemmine. J Controlled Release 97 2 (2004) 357-369
26. Veiseh M., Gabikian P., Bahrami S.B., Veiseh O., Zhang M., Hackman R.C., et al. Tumor paint: a Chlorotoxin: Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 67 14 (2007) 6882-6888
27. Lyons S.A., O'Neal J., and SontheimerChlorotoxin H. a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 39 2 (2002) 162-173
28. Sun C., Veiseh O., Gunn J., Fang C., Hansen S., Lee D., et al. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 4 3 (2008) 372-379
29. Veiseh O., Sun C., Gunn J., Kohler N., Gabikian P., Lee D., et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 5 6 (2005) 1003-1008
30. Shen S., Khazaeli M., Gillespie G.Y., and Alvarez V.L. Radiation dosimetry of I-131-chlorotoxin for targeted radiotherapy in glioma-bearing mice. J Neurooncol 71 2 (2005) 113-119
31. Eliyahu H., Barenholz Y., and Domb A.J. Polymers for DNA delivery. Molecules 10 1 (2005) 34-64
32. Duncan R., Ringsdorf H., and Satchi-Fainaro R. Polymer therapeutics: polymers as drugs, drug and protein conjugates and gene delivery systems: past, present and future opportunities. Polymer therapeutics I: polymers as drugs, conjugates and gene delivery systems (2006), Springer-Verlag Berlin, Berlin p. 1-8
33. Peer D., Karp J.M., Hong S., FaroKhzad O.C., Margalit R., and Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2 12 (2007) 751-760
34. Hunter A.C. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv Drug Deliv Rev 58 14 (2006) 1523-1531
35. McFerrin M.B., and Sontheimer H. A role for ion channels in glioxna cell invasion. Neuron Glia Biol 2 (2006) 39-49
36. Petersen H., Fechner P.M., Fischer D., and Kissel T. Synthesis, characterization, and biocompatibility of polyethylenimine-graft-poly(ethylene glycol) block copolymers. Macromolecules 35 18 (2002) 6867-6874